title: Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib.
authors.forename: S
authors.initials: S
authors.lastname: Boeck
authors.forename: A
authors.initials: A
authors.lastname: Wollenberg
authors.forename: V
authors.initials: V
authors.lastname: Heinemann
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000284:Administration, Oral; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D007866:Leg; D008113:Liver Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects*; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride